title: Successful management of severe infant bullous pemphigoid with omalizumab.
authors.forename: C
authors.initials: C
authors.lastname: Dufour
authors.forename: A L
authors.initials: AL
authors.lastname: Souillet
authors.forename: C
authors.initials: C
authors.lastname: Chaneliere
authors.forename: F
authors.initials: F
authors.lastname: Jouen
authors.forename: C
authors.initials: C
authors.lastname: Bodemer
authors.forename: D
authors.initials: D
authors.lastname: Jullien
authors.forename: F
authors.initials: F
authors.lastname: Cambazard
authors.forename: P
authors.initials: P
authors.lastname: Joly
authors.forename: P
authors.initials: P
authors.lastname: Reix
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D000069444:Omalizumab; D010391:Pemphigoid, Bullous / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D000069444:Omalizumab